Evaluating the real-world impact of first line PARP inhibitor maintenance therapy in patients with BRCA mutated ovarian tumors

PARP-inhibitor (PARPi) treatment in patients with BRCA-mutated ovarian malignancy has been shown to prolong survival in randomized control trials in the first-line setting. However, uptake and response to treatment have been variable. Thus, we sought to evaluate an institutional “real-world” use and clinical impact of PARPi in the first-line maintenance setting in patients with BRCA mutations.